Results 11 to 20 of about 9,643 (207)

Biosimilars [PDF]

ESMO Open, 2018
Linked article: This is a commentary on P. Yamauchi et al., pp. 1066–1074 in this issue.
Sandeep, Parsad, Chadi, Nabhan
  +9 more sources

Biosimilars [PDF]

Therapeutische Umschau, 2011
Die Bewertung von Biosimilars stellt eine Herausforderung für alle an der Zulassung und an der Arzneimittelauswahl Beteiligten im Gesundheitswesen dar. Bewertungskriterien sind wie bei allen Arzneimitteln Qualität, Wirksamkeit, Sicherheit/Verträglichkeit und Wirtschaftlichkeit.
openaire   +6 more sources

Etanercept biosimilars [PDF]

Rheumatology International, 2014
Etanercept was the first tumour necrosis factor alpha antagonist approved in the USA for the treatment of rheumatoid arthritis, in 1998, and then for other diseases. With the etanercept patent set to expire in the EU in 2015, a number of etanercept copies have reached the production phase and are undergoing clinical trials, with the promise of being ...
Azevedo, Valderilio F., Galli, Nathalia, Kleinfelder, Alais, D’Ippolito, Julia, Urbano, Paulo C. M.   +4 more
openaire   +2 more sources

Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars

Терапевтический архив, 2021
Aim. To define the frequency of adverse events and loss of the response in patients with ulcerative colitis (UC) and Crohns disease (CD), treated with original medicine infliximab (IFX) Remicaide and its biosimilars. Materials and methods. We included
O. V. Knyazev, M. Yu. Zvyaglova, A. V. Kagramanova, I. A. Li, E. A. Sabelnikova, A. A. Lishchinskaya, D. S. Kulakov, A. I. Parfenov   +7 more
doaj   +1 more source

What do oncologists need to know about biosimilar products?

Chinese Journal of Cancer, 2016
Many biologic products have improved the outcomes of cancer patients, but the costs can substantially burden healthcare systems. Biosimilar products can potentially reduce drug costs and increase patient access to beneficial treatments.
Linda K. S. Leung, Kevin Mok, Calvin Liu, Stephen L. Chan   +3 more
doaj   +1 more source

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices

ACR Open Rheumatology, 2020
Objective It is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility.
Nick Bansback, Jeffrey R. Curtis, Jie Huang, Zeling He, Michael Evans, Tracy Johansson, Kaleb Michaud, Gabriela Schmajuk, Katherine P. Liao   +8 more
doaj   +1 more source

Key drivers for market penetration of biosimilars in Europe

Journal of Market Access & Health Policy, 2017
Background & Objectives: Potential drivers and barriers of biosimilar uptake were mainly analysed through qualitative approaches. The study objective was to conduct a quantitative analysis and identify drivers of biosimilar uptake of all available ...
Cécile Rémuzat, Julie Dorey, Olivier Cristeau, Dan Ionescu, Guerric Radière, Mondher Toumi   +5 more
doaj   +1 more source

Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends

Frontiers in Pharmacology, 2023
Background: Factors like the number of biosimilar competitors and competitive pricing strategies from originator companies may influence price competition and biosimilar uptake.Objective: The aim of this study was to analyze multiple facets of biosimilar
Elif Car, Arnold G. Vulto, Arnold G. Vulto, Mark Van Houdenhoven, Isabelle Huys, Steven Simoens   +5 more
doaj   +1 more source

Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study

Biomedicines, 2022
This study aimed to compare adalimumab originator vs. biosimilar in HS patients, and to evaluate the effect of a switch to a biosimilar, or a switch back to the originator, in terms of treatment ineffectiveness.
Martina Burlando, Gabriella Fabbrocini, Claudio Marasca, Paolo Dapavo, Andrea Chiricozzi, Dalma Malvaso, Valentina Dini, Anna Campanati, Annamaria Offidani, Annunziata Dattola, Raffaele Dante Caposiena Caro, Luca Bianchi, Marina Venturini, Paolo Gisondi, Claudio Guarneri, Giovanna Malara, Caterina Trifirò, Piergiorigio Malagoli, Maria Concetta Fargnoli, Stefano Piaserico, Luca Carmisciano, Riccardo Castelli, Aurora Parodi   +22 more
doaj   +1 more source

Biosimilar: what it is not [PDF]

British Journal of Clinical Pharmacology, 2015
A biosimilar is a high quality biological medicine shown to be in essence the same as an original product. The European Medicines Agency (EMA) paved the way in the regulatory arena by creating a safeguarding framework for the development of biosimilars.
openaire   +2 more sources